After two years, COTA was back together in NYC for an in-person all-hands meeting. As much as we have learned to adapt to the world of remote work, there is no substitute for the connection, collaboration, and energy that comes from physically being in the same space.
Enterprise Data Strategies for Life Sciences with Datavant’s Su Huang
In this episode of Real World Talk we welcome Su Huang, the Head of Data Strategy at Datavant. Su shares real-world experiences implementing enterprise data strategies and the efficiencies that can be gained when teams across an organization are involved in the process.
How Standardization and Consistency Help With Using Real World Data in Clinical Research
Unlike the controlled settings under which clinical trials are conducted, real-world data is collected from a variety of settings. The FDA recently released draft guidance on how to use real-world data for regulatory submissions. Our team of clinical experts discuss this guidance and its effect on how we generate and apply RWD in clinical development.
Using Real World Data to Improve Blood Cancer Treatments with Dr. Gwen Nichols
Almost 10% of the world’s population suffers from a type of blood cancer. And despite popular opinion, there are actually hundreds of different types of blood cancer, not just leukemia and lymphoma.
But are we doing everything in our power when developing clinical trials to improve cancer treatment? Could we include diversity and make trials more accessible to everyone? Our guest today thinks we have more work to do in the blood cancer space.
In this episode of the Real World Talk podcast, our host Miruna Sasu welcomes Dr.Gwen Nichols, Executive Vice President and Chief Medical Officer of The Leukemia & Lymphoma Society (LLS). We discuss the importance of making clinical trials more diverse and feasible for patients. We also get into Dr. Gwen’s predictions for the future and why she thinks there’s hope for earlier cancer detection and prevention.
Discover more about how our work with the FDA, industry and academia helps to ensure that everyone touched by cancer is given a clear path to the right care.
ASH 2020: Real-World Treatment Patterns and Outcomes of Patients with Functional High-Risk (Early Relapse) Multiple Myeloma
In collaboration with researchers from the University of Texas Southwestern Medical Center, this retrospective study uses RWD to explore treatment patterns and outcomes of functional high-risk multiple myeloma patients who relapse within 18 months of initial diagnosis.
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
In this retrospective observational cohort study involving 13 hospitals within the Hackensack Meridian Health network (NJ, USA), patients with COVID-19 requiring ICU support who received tocilizumab had reduced mortality. Results of ongoing randomized controlled trials are awaited.
ESMO IO 2019: Cost of Adverse Events (AEs) With Second-line (2L) Immuno-Oncology Agents (IO) and Chemotherapy (CHEMO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) in the Real World
In collaboration with Bristol-Myers Squibb, COTA investigated the incidence and cost of adverse events among aNSCLC patients treated with 2L immuno-oncology agents as compared to 2L chemotherapy, finding lower cost among patients treated with IO.
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer
COTA was one of six organizations to participate in a collaboration to explore the consistency of real-world endpoints across diverse datasets and the potential validity of RWD to support regulatory and payer decision making.
ASCO 2019: Rates of Genotyping for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair in Metastatic Colon Cancer Patients: Gaps and Implications.
In collaboration with Guardant Health, COTA investigated the molecular testing rates of patients with metastatic colon cancer and found that <25% of our cohort received guideline recommended genotyping.
Paying participants isn’t the way to improve clinical trial recruitment
It’s notoriously difficult to recruit people to participate in clinical trials. It’s even harder to ensure that trials are ethnically, racially, and socioeconomically diverse. The idea of paying people to participate has been floated as an option to improve recruitment, but I believe fundamental problems in the clinical trial mechanism need to be addressed before moving in that direction.
The Pace Of Covid-19 Vaccine Development Makes Cancer Research Seem Too Slow, New Study Shows
The speed of Covid-19 vaccine development hasn’t just made some Americans nervous about getting vaccinated. It’s also helped raise consumer expectations about how quickly scientific progress can happen, particularly in cancer care.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.